Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2012

View Archived Issues

Scientists disclose new CD27-targeted candidate immunotherapeutics

GlaxoSmithKline presents highlights of 2011

Novel epithelial sodium channel blockers identified at Novartis

Metal chelators protect against proteins linked to neurodegenerative disorders

New antimicrobials specifically target NAD+-dependent DNA ligases

Antisense Therapeutics provides update on second-generation product

Neuropeptide W/neuropeptide B NPBW1 receptor antagonists described

New candidate cancer immunotherapies developed in France

Merck & Co. reports novel antibacterial immunotherapies

Novel products for hemophilia designed at Novo Nordisk

New bile acid GPBA receptor agonists developed at Roche

U.S. university patents new microRNA-based cancer therapies

Roche reports novel kinase inhibitors

U.S. scientists identify first inhibitors of menin/MLL fusion protein interaction

Alexza Pharmaceuticals receives first feedback on Adasuve MAA

Valeant Pharmaceuticals announces planned acquisition

BioDiem grants exclusive license for LAIV vaccine technology

Advanced Cell Technology treats third patient in phase I/II stem cell study

Celsion kicks off enrollment in ThermoDox trial

Phase III StemEx study is fully enrolled

Karo Bio discontinues development of eprotirome

Amylin Pharmaceuticals launches Bydureon in U.S.

CPP-115 receives European orphan drug status

FDA approves first preservative-free tafluprost ophthalmic solution

FDA grants priority review to Truvada sNDA

Cyclacel reports interim phase II data on sapacitabine in MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.